

Qiu-Yan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1103456/publications.pdf>

Version: 2024-02-01

109
papers

3,107
citations

218677

26
h-index

197818

49
g-index

114
all docs

114
docs citations

114
times ranked

2666
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy. <i>Head and Neck</i> , 2022, 44, 113-121.	2.0	1
2	Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1163-1173.	1.6	25
3	EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. <i>Cell Death and Differentiation</i> , 2022, 29, 1513-1527.	11.2	45
4	Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model. <i>Radiotherapy and Oncology</i> , 2022, 167, 252-260.	0.6	2
5	Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2022, 163, 26-34.	2.8	10
6	Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients. <i>Radiotherapy and Oncology</i> , 2022, 168, 61-68.	0.6	3
7	Definitive radiation therapy and liver local therapy in de novo liver metastatic nasopharyngeal carcinoma: Large cohort study. <i>Head and Neck</i> , 2022, , .	2.0	1
8	Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020. <i>JAMA Network Open</i> , 2022, 5, e220173.	5.9	3
9	Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 706.	7.1	22
10	Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission. <i>Oral Oncology</i> , 2022, 128, 105851.	1.5	2
11	Determining the suitability of definitive radiation therapy in patients with metastatic nasopharyngeal carcinoma based on PET/CT: a large cohort study. <i>European Radiology</i> , 2022, , 1.	4.5	1
12	Construction and validation of a biochemical signature to predict the prognosis and the benefit of induction chemotherapy in patients with nasopharyngeal carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1635-1647.	1.4	0
13	Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. <i>Cancer Research</i> , 2021, 81, 1413-1425.	0.9	19
14	Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study. <i>Cancer Biology and Medicine</i> , 2021, 19, 551-564.	3.0	3
15	Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage II nasopharyngeal carcinoma: a nest case-control study. <i>European Radiology</i> , 2021, 31, 5222-5233.	4.5	5
16	Efficacy of Transnasal Endoscopic Fine-Needle Aspiration Biopsy in Diagnosing Submucosal Nasopharyngeal Carcinoma. <i>Laryngoscope</i> , 2021, 131, 1798-1804.	2.0	4
17	Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. <i>Nature Communications</i> , 2021, 12, 741.	12.8	104
18	Cigarette smoke-associated inflammation impairs bone remodeling through NF- κ B activation. <i>Journal of Translational Medicine</i> , 2021, 19, 163.	4.4	12

#	ARTICLE	IF	CITATIONS
19	Geriatric nutritional risk index as an independent prognostic factor in locally advanced nasopharyngeal carcinoma treated using radical concurrent chemoradiotherapy: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2021, 9, 532-532.	1.7	8
20	Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy. <i>BMC Cancer</i> , 2021, 21, 534.	2.6	11
21	A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4186-4194.	7.0	15
22	Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 160, 9-17.	0.6	2
23	Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 627935.	3.5	5
24	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	30.7	197
25	Impact of smoking on survival in nasopharyngeal carcinoma: A cohort study with 23,325 patients diagnosed from 1990 to 2016. <i>Radiotherapy and Oncology</i> , 2021, 162, 7-17.	0.6	7
26	Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment. <i>Radiotherapy and Oncology</i> , 2021, 162, 202-211.	0.6	5
27	Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?. <i>Radiotherapy and Oncology</i> , 2021, 163, 185-191.	0.6	3
28	Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?. <i>Oral Oncology</i> , 2021, 122, 105539.	1.5	4
29	Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2586-2598.	6.4	8
30	Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: A study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA. <i>Head and Neck</i> , 2021, , .	2.0	10
31	Alpha-fetoprotein-producing recurrent nasopharyngeal carcinoma: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110577.	0.3	0
32	Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. <i>European Journal of Cancer</i> , 2021, 159, 133-143.	2.8	3
33	Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2021, 21, 1320.	2.6	4
34	Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2138470.	5.9	9
35	Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage IIa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort. <i>Cancer Medicine</i> , 2020, 9, 1661-1670.	2.8	8
36	Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up. <i>Oral Oncology</i> , 2020, 100, 104490.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2020, 10, 543646.	2.8	7
38	Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages IIâ€“IVb Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 539321.	2.8	6
39	Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1295.	2.8	4
40	Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage IIâ€“IVb Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 579292.	2.8	1
41	Identifying optimal candidates for induction chemotherapy among stage IIâ€“IVa nasopharyngeal carcinoma based on pretreatment Epsteinâ€“Barr virus DNA and nodal maximal standard uptake values of [18 F]â€“fluorodeoxyglucose positron emission tomography. <i>Cancer Medicine</i> , 2020, 9, 8852-8863.	2.8	3
42	Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. <i>Cell Research</i> , 2020, 30, 950-965.	12.0	111
43	Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092821.	3.2	5
44	Stratification of Candidates for Induction Chemotherapy in Stage III-IV Nasopharyngeal Carcinoma: A Large Cohort Study Based on a Comprehensive Prognostic Model. <i>Frontiers in Oncology</i> , 2020, 10, 255.	2.8	10
45	Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases. <i>Head and Neck</i> , 2020, 42, 1970-1980.	2.0	13
46	Lymph-node Epsteinâ€“Barr virus concentration in diagnosing cervical lymph-node metastasis in nasopharyngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2513-2520.	1.6	4
47	Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. <i>Oncogenesis</i> , 2020, 9, 65.	4.9	52
48	Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epsteinâ€“Barr virus DNA level. <i>BMC Cancer</i> , 2020, 20, 89.	2.6	8
49	The role of capecitabine as maintenance therapy in <i>de novo</i> metastatic nasopharyngeal carcinoma: A propensity score matching study. <i>Cancer Communications</i> , 2020, 40, 32-42.	9.2	16
50	Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2020, 106, 104711.	1.5	10
51	Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. , 2020, 8, e000205.		26
52	Intensive Local Radiotherapy Is Associated With Better Local Control and Prolonged Survival in Bone-Metastatic Nasopharyngeal Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 378.	2.8	7
53	Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epsteinâ€“Barr virus DNA level after induction chemotherapy. <i>Aging</i> , 2020, 12, 4931-4944.	3.1	8
54	Establishment of a prognostic scoring model for regional recurrent nasopharyngeal carcinoma after neck dissection. <i>Cancer Biology and Medicine</i> , 2020, 17, 227-236.	3.0	9

#	ARTICLE	IF	CITATIONS
55	Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis. <i>Oral Oncology</i> , 2019, 97, 31-36.	1.5	2
56	The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the Survival of Patients With Nasopharyngeal Carcinoma: A Cohort Study From 1990 to 2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 581-590.	0.8	80
57	<p>The development of a nomogram to predict post-radiation necrosis in nasopharyngeal carcinoma patients: a large-scale cohort study<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6253-6263.	1.9	13
58	Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study. <i>Cancer Medicine</i> , 2019, 8, 6841-6852.	2.8	22
59	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2019, 119, 87-96.	2.8	150
60	Maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients. <i>BMC Cancer</i> , 2019, 19, 908.	2.6	8
61	Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. <i>BMC Cancer</i> , 2019, 19, 92.	2.6	33
62	Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1999-2012.	2.5	29
63	Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2019, 94, 73-79.	1.5	12
64	Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. <i>Radiotherapy and Oncology</i> , 2019, 137, 83-94.	0.6	44
65	Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial. <i>Supportive Care in Cancer</i> , 2019, 27, 3759-3767.	2.2	18
66	Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients. <i>Oral Oncology</i> , 2019, 92, 40-45.	1.5	17
67	The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. <i>Cancer Communications</i> , 2019, 39, 1-13.	9.2	24
68	Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019, 110, 24-31.	2.8	40
69	STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. <i>Cell Death and Differentiation</i> , 2019, 26, 2314-2328.	11.2	81
70	The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis. <i>Journal of Cancer</i> , 2019, 10, 5614-5621.	2.5	11
71	Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance. <i>Cancer Research and Treatment</i> , 2019, 51, 1259-1268.	3.0	18
72	Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1449-1463.	3.0	11

#	ARTICLE	IF	CITATIONS
73	Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 461-473.	10.7	118
74	Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study. <i>Cancer Research and Treatment</i> , 2018, 50, 701-711.	3.0	14
75	Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2018, 18, 1279.	2.6	13
76	Symptomatic venous thromboembolism associated with peripherally inserted central catheters predicts a worse survival in nasopharyngeal carcinoma: results of a large cohort, propensity score-matched analysis. <i>BMC Cancer</i> , 2018, 18, 1297.	2.6	9
77	Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study. <i>Cancer Communications</i> , 2018, 38, 1-13.	9.2	20
78	The prognosis of neck residue nasopharyngeal carcinoma (NPC) patients: results from a case-cohort study. <i>Journal of Cancer</i> , 2018, 9, 1765-1772.	2.5	3
79	Patterns of Failure and Survival Trends Of 720 Patients with Stage I Nasopharyngeal Carcinoma Diagnosed from 1990-2012: A Large-scale Retrospective Cohort Study. <i>Journal of Cancer</i> , 2018, 9, 1308-1317.	2.5	11
80	The incidence and predictors of symptomatic venous thromboembolism associated with peripherally inserted central catheters in patients with nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3119-3127.	2.0	8
81	Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. <i>BMC Cancer</i> , 2018, 18, 114.	2.6	13
82	The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. <i>Cancer Research and Treatment</i> , 2018, 50, 19-29.	3.0	56
83	Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study. <i>Cancer Research and Treatment</i> , 2018, 50, 861-871.	3.0	38
84	Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. <i>Cancer Research and Treatment</i> , 2018, 50, 1304-1315.	3.0	19
85	CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 21.	8.6	26
86	Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2017, 75, 14-23.	2.8	226
87	Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival. <i>Radiology</i> , 2017, 282, 171-181.	7.3	11
88	Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. <i>BMC Cancer</i> , 2017, 17, 567.	2.6	29
89	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥ 4000 copies/ml: a matched study. <i>Oncotarget</i> , 2016, 7, 29739-29748.	1.8	15
90	With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study. <i>BMC Cancer</i> , 2016, 16, 774.	2.6	17

#	ARTICLE	IF	CITATIONS
91	Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv291.	6.3	281
92	IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. <i>Oncotarget</i> , 2016, 7, 68140-68150.	1.8	10
93	Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. <i>Oncotarget</i> , 2016, 7, 6221-6230.	1.8	37
94	LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome. <i>Oncotarget</i> , 2016, 7, 8200-8207.	1.8	14
95	Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13060-13068.	1.8	80
96	Prognostic effect of pregnancy on young female patients with nasopharyngeal carcinoma: results from a matched cohort analysis. <i>Oncotarget</i> , 2016, 7, 21913-21921.	1.8	4
97	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2015, 15, 977.	2.6	21
98	Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 237-46.	4.9	44
99	Is Hemoglobin Level in Patients with Nasopharyngeal Carcinoma Still a Significant Prognostic Factor in the Era of Intensity-Modulated Radiotherapy Technology?. <i>PLoS ONE</i> , 2015, 10, e0136033.	2.5	28
100	High-Sensitivity C-Reactive Protein Complements Plasma Epstein-Barr Virus Deoxyribonucleic Acid Prognostication in Nasopharyngeal Carcinoma: A Large-Scale Retrospective and Prospective Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 325-336.	0.8	41
101	The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 862-869.	0.8	110
102	Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncolmmunology</i> , 2015, 4, e976507.	4.6	61
103	COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. <i>Oncolmmunology</i> , 2015, 4, e1044712.	4.6	79
104	Different Prognostic Values of Plasma Epstein-Barr Virus DNA and Maximal Standardized Uptake Value of 18F-FDG PET/CT for Nasopharyngeal Carcinoma Patients with Recurrence. <i>PLoS ONE</i> , 2015, 10, e0122756.	2.5	27
105	Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 38296-38307.	1.8	10
106	Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 44037-44048.	1.8	25
107	The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. <i>Radiation Oncology</i> , 2014, 9, 246.	2.7	15
108	Optimal multivariate method for Raman spectroscopy based diagnosis of nasopharyngeal carcinoma. <i>Journal of Applied Physics</i> , 2013, 114, 244702.	2.5	5

#	ARTICLE	IF	CITATIONS
109	A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 1038-1044.	1.5	65